公开(公告)号：US20240335385A1

公开(公告)日：2024-10-10

申请号：US18746810

申请日：2024-06-18

申请人： Beam Therapeutics Inc.

发明人： Cory Dane SAGO ,  Gregory Lawrence HAMILTON

IPC分类号： A61K9/127 ,  A61K31/7105 ,  A61K39/00 ,  A61K39/385 ,  A61K47/10 ,  A61K47/24 ,  A61K47/28 ,  A61K48/00 ,  C07C219/16 ,  C07D211/22 ,  C07D295/15

CPC分类号： A61K9/1272 ,  A61K31/7105 ,  A61K39/385 ,  A61K47/10 ,  A61K47/24 ,  A61K47/28 ,  A61K48/0033 ,  C07C219/16 ,  C07D211/22 ,  C07D295/15 ,  A61K2039/6018

摘要： The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.

公开(公告)号：US20240226287A1

公开(公告)日：2024-07-11

申请号：US18536271

申请日：2023-12-12

申请人： KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION

发明人： Eun-Kyoung Bang ,  GYO CHANG KEUM ,  Jae- Hwan Nam ,  Seohyeon Bae ,  Muhammad Faisal ,  Sung Pil Kwon ,  Soyeon Yoo

IPC分类号： A61K39/39 ,  A61K47/26 ,  C07C235/08 ,  C07C235/10 ,  C07D207/04 ,  C07D211/06 ,  C07D213/55 ,  C07D231/12 ,  C07D265/30 ,  C07D295/15 ,  C07D339/04 ,  C07D413/10 ,  C12N15/113

CPC分类号： A61K39/39 ,  A61K47/26 ,  C07C235/08 ,  C07C235/10 ,  C07D207/04 ,  C07D211/06 ,  C07D213/55 ,  C07D231/12 ,  C07D265/30 ,  C07D295/15 ,  C07D339/04 ,  C07D413/10 ,  C12N15/113 ,  A61K2039/55555 ,  C07C2601/16

摘要： The present disclosure relates to a novel lipid compound and a lipid nanoparticle composition including the same and, more specifically, the lipid nanoparticle composition includes ionized lipid, helper lipid, PEG-lipid, and additives, and may mitigate changes and side effects in the delivery mechanism and enhance the protein expression efficiency by including a biofriendly vitamin-based novel lipid compound and helper lipids including neutral lipids.

公开(公告)号：US20240116860A1

公开(公告)日：2024-04-11

申请号：US18508202

申请日：2023-11-13

申请人： The Board of Regents of The University of Texas System

发明人： Daniel J. SIEGWART ,  Kejin ZHOU

IPC分类号： C07C321/14 ,  A61K9/51 ,  A61K31/7105 ,  A61K31/7125 ,  A61K47/20 ,  A61K47/22 ,  A61K47/59 ,  A61K47/60 ,  A61K47/69 ,  A61K48/00 ,  C07C323/52 ,  C07D295/15

CPC分类号： C07C321/14 ,  A61K9/513 ,  A61K9/5146 ,  A61K31/7105 ,  A61K31/7125 ,  A61K47/20 ,  A61K47/22 ,  A61K47/59 ,  A61K47/60 ,  A61K47/6931 ,  A61K48/0041 ,  C07C323/52 ,  C07D295/15

摘要： Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.

公开(公告)号：US20240083842A1

公开(公告)日：2024-03-14

申请号：US18508211

申请日：2023-11-13

申请人： The Board of Regents of The University of Texas System

发明人： Daniel J. SIEGWART ,  Kejin ZHOU

IPC分类号： C07C321/14 ,  A61K9/51 ,  A61K31/7105 ,  A61K31/7125 ,  A61K47/20 ,  A61K47/22 ,  A61K47/59 ,  A61K47/60 ,  A61K47/69 ,  A61K48/00 ,  C07C323/52 ,  C07D295/15

CPC分类号： C07C321/14 ,  A61K9/513 ,  A61K9/5146 ,  A61K31/7105 ,  A61K31/7125 ,  A61K47/20 ,  A61K47/22 ,  A61K47/59 ,  A61K47/60 ,  A61K47/6931 ,  A61K48/0041 ,  C07C323/52 ,  C07D295/15

摘要： Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.

公开(公告)号：US20240043378A1

公开(公告)日：2024-02-08

申请号：US18335960

申请日：2023-06-15

申请人： The Board of Regents of The University of Texas System

发明人： Daniel J. SIEGWART ,  Kejin ZHOU

IPC分类号： C07C321/14 ,  A61K47/59 ,  C07C323/52 ,  A61K9/51 ,  A61K47/69 ,  A61K47/60 ,  A61K31/7105 ,  A61K48/00 ,  A61K31/7125 ,  A61K47/20 ,  A61K47/22 ,  C07D295/15

CPC分类号： C07C321/14 ,  A61K47/59 ,  C07C323/52 ,  A61K9/5146 ,  A61K47/6931 ,  A61K47/60 ,  C07D295/15 ,  A61K31/7105 ,  A61K48/0041 ,  A61K31/7125 ,  A61K47/20 ,  A61K47/22 ,  A61K9/513

摘要： Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.

公开(公告)号：US11827582B2

公开(公告)日：2023-11-28

申请号：US16836835

申请日：2020-03-31

申请人： ACELOT, INC.

发明人： Ambuj K. Singh ,  Christian A. Lang

IPC分类号： C07C211/23 ,  C07C233/43 ,  C07C271/18 ,  A61K31/135 ,  A61K31/137 ,  C07C223/02 ,  C07C211/28 ,  C07C211/29 ,  A61K31/131 ,  C07C211/27 ,  C07C217/60 ,  C07D207/06 ,  C07D295/135 ,  C07D295/15 ,  C07D319/18 ,  C07D413/06

CPC分类号： C07C233/43 ,  A61K31/131 ,  A61K31/135 ,  A61K31/137 ,  C07C211/27 ,  C07C211/28 ,  C07C211/29 ,  C07C217/60 ,  C07C223/02 ,  C07C271/18 ,  C07D207/06 ,  C07D295/135 ,  C07D295/15 ,  C07D319/18 ,  C07D413/06

摘要： The present disclosure provides small molecule drugs and pharmaceutical compositions for the treatment and prevention of diseases related to the formation of Aβ42 oligomers in a subject. It further provides a method of reducing formation of or disrupting Aβ42 oligomers in a subject, the method comprising the step of administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition. One such compound is a compound of formula 120:

公开(公告)号：US11708329B2

公开(公告)日：2023-07-25

申请号：US16962751

申请日：2019-01-30

申请人： The Regents of the University of California

发明人： Michael E. Jung ,  Xiaohong Chen ,  Cun-Yu Wang ,  Jiong Li ,  Jie Zheng

IPC分类号： C07D213/06 ,  C07D213/38 ,  C07D213/40 ,  C07D213/50 ,  C07D213/55 ,  C07D213/68 ,  C07C237/38 ,  A61P35/00 ,  C07C235/62 ,  C07C237/04 ,  C07C311/07 ,  C07D211/86 ,  C07D213/89 ,  C07D295/088 ,  C07D295/15 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14

CPC分类号： C07D213/68 ,  A61P35/00 ,  C07C235/62 ,  C07C237/04 ,  C07C237/38 ,  C07C311/07 ,  C07D211/86 ,  C07D213/06 ,  C07D213/38 ,  C07D213/40 ,  C07D213/50 ,  C07D213/55 ,  C07D213/89 ,  C07D295/088 ,  C07D295/15 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14

摘要： The present disclosure relates to compounds that are capable of modulating the WNT/Beta-Catenin pathway. The disclosure further relates to methods of treating colorectal cancer and other WNT/Beta-Catenin mediated cancers.

公开(公告)号：US20230151060A1

公开(公告)日：2023-05-18

申请号：US17773733

申请日：2020-11-05

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA

发明人： Mikimasa TANADA ,  Koji TAKANO ,  Atsushi MATSUO ,  Minoru TAMIYA ,  Aya CHIYODA ,  Toshiya ITO ,  Takeo IIDA

IPC分类号： C07K7/64 ,  C07D211/38 ,  C07C271/22 ,  C07D213/55 ,  C07D213/65 ,  C07D213/64 ,  C07D213/61 ,  C07D205/04 ,  C07C323/09 ,  C07F5/02 ,  C07D309/12 ,  C07C317/04 ,  C07D409/12 ,  C07D333/28 ,  C07D295/15

CPC分类号： C07K7/64 ,  C07D211/38 ,  C07C271/22 ,  C07D213/55 ,  C07D213/65 ,  C07D213/64 ,  C07D213/61 ,  C07D205/04 ,  C07C323/09 ,  C07F5/025 ,  C07D309/12 ,  C07C317/04 ,  C07D409/12 ,  C07D333/28 ,  C07D295/15 ,  A61K38/00

摘要： The present inventors found cyclic peptide compounds that interact with Ras, and non-natural amino acids useful for the production of the cyclic peptide compounds. The inventors also found that the cyclic peptide compounds inhibit the binding between Ras and SOS. In addition, the inventors found specific non-natural amino acids contained in the cyclic peptide compounds and methods for production thereof.

公开(公告)号：US11634398B2

公开(公告)日：2023-04-25

申请号：US16576178

申请日：2019-09-19

申请人： Celex Oncology Ltd.

发明人： Mustafa Djamgoz

IPC分类号： C07D295/15 ,  A61K31/00 ,  A61K31/428 ,  A61K31/495 ,  A61K31/138 ,  A61K31/167 ,  A61K31/19 ,  A61K31/4458 ,  C07D241/04 ,  C07D277/82

摘要： Substances and methods are dislosed for reducing or preventing metastatic behaviour in VGSC expressing cancer by the effect of at least reducing the persistent part of the voltage gated sodium channel current without eliminating the transient part. Inhibition of metastatic cell behaviours such as detachability, lateral motility, transverse migration and invasiveness is demonstrated using the known drugs ranolazine and riluzole.

公开(公告)号：US20230053437A1

公开(公告)日：2023-02-23

申请号：US17785315

申请日：2021-08-19

申请人： Suzhou Abogen Biosciences Co., Ltd.

发明人： Bo Ying

IPC分类号： A61K39/00 ,  C07D211/22 ,  C07D295/15 ,  C07D401/12 ,  C07D473/40 ,  C07D211/34 ,  A61K9/127 ,  A61K31/7115

摘要： Provided herein are lipid compounds that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules) for therapeutic or prophylactic purposes, including vaccination. Also provided herein are lipid nanoparticle compositions comprising said lipid compounds.